Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles

Autor: Massimiliano Perduca, Stefano Dusi, Marta Donini, Piyachat Evelyn Denbaes, Salvatore Calogero Gaglio
Jazyk: angličtina
Rok vydání: 2021
Předmět:
medicine.medical_treatment
Anti-Inflammatory Agents
Pharmaceutical Science
Inflammation
Article
Analytical Chemistry
lcsh:QD241-441
03 medical and health sciences
chemistry.chemical_compound
oxyresveratrol
Drug Delivery Systems
0302 clinical medicine
Immune system
Polylactic Acid-Polyglycolic Acid Copolymer
lcsh:Organic chemistry
Stilbenes
Drug Discovery
medicine
Humans
Secretion
dendritic cells
Physical and Theoretical Chemistry
030304 developmental biology
Dendritic cells
Oxyresveratrol
Cytokines
PLGA nanoparticles
Drug Carriers
0303 health sciences
Plant Extracts
Organic Chemistry
Imidazoles
Drug Synergism
cytokines
Cell biology
PLGA
Cytokine
chemistry
Chemistry (miscellaneous)
inflammation
030220 oncology & carcinogenesis
Nanoparticles
Molecular Medicine
Cytokine secretion
Inflammation Mediators
Resiquimod
medicine.symptom
Zdroj: Molecules
Molecules, Vol 26, Iss 2106, p 2106 (2021)
Volume 26
Issue 8
ISSN: 1420-3049
Popis: Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this therapeutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of the pro-inflammatory cytokines IL-12, IL-6, and TNF-α by human dendritic cells (DCs). We found that oxyresveratrol did not elicit per se the release of these cytokines, but inhibited their secretion induced upon DC stimulation with R848 (Resiquimod), a well-known immune cell activator engaging receptors recognizing RNA viruses. We then investigated whether the inclusion of oxyresveratrol into nanoparticles promoting its ingestion by DCs could favor its effects on cytokine release. For this purpose we synthesized and characterized poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and we assessed their effects on DCs. We found that bare PLGA nanoparticles did not affect cytokine secretion by resting DCs, but increased IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs, an event known as “priming effect”. We then loaded PLGA nanoparticles with oxyresveratrol and we observed that oxyresveratrol-bearing particles did not stimulate the cytokine release by resting DCs and inhibited the PLGA-dependent enhancement of IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs. The results herein reported indicate that oxyresveratrol suppresses the cytokine production by activated DCs, thus representing a good anti-inflammatory and immune-suppressive agent. Moreover, its inclusion into PLGA nanoparticles mitigates the pro-inflammatory effects due to cooperation between nanoparticles and R848 in cytokine release. Therefore, oxyresveratrol can be able to contrast the synergistic effects of nanoparticles with microorganisms that could be present in the patient tissues, therefore overcoming a condition unfavorable to the use of some nanoparticles in biological systems.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje